Groupama Asset Managment Acquires 145,799 Shares of GSK plc (NYSE:GSK)

Groupama Asset Managment lifted its stake in GSK plc (NYSE:GSK) by 11.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,413,089 shares of the pharmaceutical company’s stock after buying an additional 145,799 shares during the period. Groupama Asset Managment owned approximately 0.07% of GSK worth $578,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Eastern Bank acquired a new position in GSK in the 3rd quarter valued at $26,000. Concord Wealth Partners increased its position in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in GSK in the second quarter valued at about $37,000. Fortitude Family Office LLC bought a new stake in GSK during the third quarter worth about $42,000. Finally, PrairieView Partners LLC bought a new stake in GSK during the second quarter worth about $47,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Activity at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 10.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 4th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 4.2 %

NYSE GSK opened at $36.01 on Tuesday. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The business’s fifty day moving average is $36.56 and its 200 day moving average is $39.50. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market cap of $74.63 billion, a price-to-earnings ratio of 23.38, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.36%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s payout ratio is 99.35%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.